Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy RAPT?
Source: PRnewswire
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, which may infringe on shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: Allegiant Travel Company’s merger with Sun Country Airlines will result in Allegiant shareholders owning approximately 67% of the combined entity, and Halper Sadeh LLC may seek increased consideration and additional disclosures.
- Cash Acquisition Scrutiny: Lisata Therapeutics, Inc. is being sold to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable rights, and Halper Sadeh LLC is assessing whether this transaction aligns with shareholder interests.
- Equity Distribution in Merger: The merger between Mission Produce, Inc. and Calavo Growers, Inc. is expected to result in Mission shareholders owning about 80.3% of the combined company, with Halper Sadeh LLC potentially advocating for higher transaction consideration and additional shareholder benefits.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RAPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RAPT
Wall Street analysts forecast RAPT stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 57.820
Low
56.00
Averages
67.78
High
95.00
Current: 57.820
Low
56.00
Averages
67.78
High
95.00
About RAPT
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, which may involve violations of shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: Allegiant Travel Company's merger with Sun Country Airlines will result in Allegiant shareholders owning approximately 67% of the combined company, with Halper Sadeh LLC assessing the fairness of the transaction and its impact on shareholders.
- Cash Acquisition Analysis: Lisata Therapeutics, Inc. is being sold to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable contingent value rights, raising concerns from Halper Sadeh LLC about whether this transaction serves the best interests of shareholders.
- Equity Distribution in Merger: The merger between Mission Produce, Inc. and Calavo Growers, Inc. is expected to result in Mission shareholders owning approximately 80.3% of the combined entity, with Halper Sadeh LLC investigating the potential implications and protections for shareholder rights.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, which may infringe on shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: Allegiant Travel Company’s merger with Sun Country Airlines will result in Allegiant shareholders owning approximately 67% of the combined entity, and Halper Sadeh LLC may seek increased consideration and additional disclosures.
- Cash Acquisition Scrutiny: Lisata Therapeutics, Inc. is being sold to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable rights, and Halper Sadeh LLC is assessing whether this transaction aligns with shareholder interests.
- Equity Distribution in Merger: The merger between Mission Produce, Inc. and Calavo Growers, Inc. is expected to result in Mission shareholders owning about 80.3% of the combined company, with Halper Sadeh LLC potentially advocating for higher transaction consideration and additional shareholder benefits.
See More
Investor Rights Investigation: Multiple Company Transactions
- Investigation Launched: Halper Sadeh LLC is investigating NorthWestern Energy Group, Inc. (NASDAQ:NWE) for its sale to Black Hills Corp., involving an exchange of 0.98 shares per NorthWestern share, which will result in shareholders owning approximately 44% of the combined entity, potentially impacting shareholder rights.
- Shareholder Rights Protection: Diamond Hill Investment Group, Inc. (NASDAQ:DHIL) is being sold to First Eagle Investments for $175.00 per share, with Halper Sadeh LLC urging shareholders to be aware of their rights, which may affect the transparency of the transaction terms.
- Legal Relief Opportunities: RAPT Therapeutics, Inc. (NASDAQ:RAPT) is being sold to GSK plc for $58.00 per share, and Halper Sadeh LLC may seek increased compensation and additional disclosures to ensure shareholders' legal rights are upheld during the transaction.
- No Upfront Fees: Halper Sadeh LLC offers legal services on a contingent fee basis, aiming to protect global investors and ensure their rights are maintained in cases of securities fraud and corporate misconduct.
See More
RAPT Therapeutics Proposed Sale to GSK Under Investigation
- Investigation Launched: Former Louisiana Attorney General Charles C. Foti and Kahn Swick & Foti law firm are investigating the proposed sale of RAPT Therapeutics to GSK, aiming to assess the adequacy of the transaction process and its terms.
- Transaction Terms Overview: Under the proposed terms, RAPT shareholders will receive $58.00 in cash per share, raising questions about whether this price adequately reflects the company's value, necessitating further scrutiny.
- Legal Rights Consultation: KSF encourages shareholders who believe the transaction undervalues the company to reach out for discussions regarding their legal rights, indicating potential disputes surrounding the deal.
- Urgency Reminder: As the transaction is structured as a tender offer, KSF emphasizes the importance of prompt action by shareholders to ensure their rights are protected.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Initiated: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc. (NASDAQ: RAPT) regarding its sale to GSK plc for $58.00 per share, potentially violating fiduciary duties to shareholders and impacting shareholder rights.
- Shareholder Rights Protection: The transaction between Penumbra, Inc. (NYSE: PEN) and Boston Scientific Corporation involves $374.00 in cash or 3.8721 shares of Boston Scientific common stock per share, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
- Cash and Stock Transaction: Calavo Growers, Inc. (NASDAQ: CVGW) is selling to Mission Produce, Inc. for $14.85 in cash and 0.9790 shares of Mission stock per share, prompting Halper Sadeh LLC to assess the potential impact of this transaction on shareholders.
- Management Transaction Review: FONAR Corporation (NASDAQ: FONR) is involved in a transaction with its CEO and certain executives for $19.00 per share for Class B common stock and $6.34 per share for Class C common stock, with Halper Sadeh LLC possibly advocating for enhanced shareholder rights.
See More
Investigation Alerts for Multiple Company Mergers
- RAPT Acquisition Investigation: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, totaling an estimated equity value of $2.2 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
- Calavo Merger Details: Calavo Growers will be acquired by Mission Produce, with shareholders receiving $27 per share, including $14.85 in cash and 0.9790 shares of Mission, valuing the transaction at approximately $430 million, while investigations examine if the board breached fiduciary duties to shareholders.
- Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific in a deal valuing the company at $374 per share, reflecting an enterprise value of about $14.5 billion, with investigations looking into whether the board ensured a fair process, potentially affecting shareholder interests.
- FONAR Merger Investigation: FONAR Corporation is to be acquired by FONAR, LLC for $19 per share in an all-cash transaction, with investigations questioning whether the board failed to conduct a fair process, which could impact shareholder rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, which may involve violations of shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: Allegiant Travel Company's merger with Sun Country Airlines will result in Allegiant shareholders owning approximately 67% of the combined company, with Halper Sadeh LLC assessing the fairness of the transaction and its impact on shareholders.
- Cash Acquisition Analysis: Lisata Therapeutics, Inc. is being sold to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable contingent value rights, raising concerns from Halper Sadeh LLC about whether this transaction serves the best interests of shareholders.
- Equity Distribution in Merger: The merger between Mission Produce, Inc. and Calavo Growers, Inc. is expected to result in Mission shareholders owning approximately 80.3% of the combined entity, with Halper Sadeh LLC investigating the potential implications and protections for shareholder rights.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, which may infringe on shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: Allegiant Travel Company’s merger with Sun Country Airlines will result in Allegiant shareholders owning approximately 67% of the combined entity, and Halper Sadeh LLC may seek increased consideration and additional disclosures.
- Cash Acquisition Scrutiny: Lisata Therapeutics, Inc. is being sold to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable rights, and Halper Sadeh LLC is assessing whether this transaction aligns with shareholder interests.
- Equity Distribution in Merger: The merger between Mission Produce, Inc. and Calavo Growers, Inc. is expected to result in Mission shareholders owning about 80.3% of the combined company, with Halper Sadeh LLC potentially advocating for higher transaction consideration and additional shareholder benefits.
See More
Investor Rights Investigation: Multiple Company Transactions
- Investigation Launched: Halper Sadeh LLC is investigating NorthWestern Energy Group, Inc. (NASDAQ:NWE) for its sale to Black Hills Corp., involving an exchange of 0.98 shares per NorthWestern share, which will result in shareholders owning approximately 44% of the combined entity, potentially impacting shareholder rights.
- Shareholder Rights Protection: Diamond Hill Investment Group, Inc. (NASDAQ:DHIL) is being sold to First Eagle Investments for $175.00 per share, with Halper Sadeh LLC urging shareholders to be aware of their rights, which may affect the transparency of the transaction terms.
- Legal Relief Opportunities: RAPT Therapeutics, Inc. (NASDAQ:RAPT) is being sold to GSK plc for $58.00 per share, and Halper Sadeh LLC may seek increased compensation and additional disclosures to ensure shareholders' legal rights are upheld during the transaction.
- No Upfront Fees: Halper Sadeh LLC offers legal services on a contingent fee basis, aiming to protect global investors and ensure their rights are maintained in cases of securities fraud and corporate misconduct.
See More
RAPT Therapeutics Proposed Sale to GSK Under Investigation
- Investigation Launched: Former Louisiana Attorney General Charles C. Foti and Kahn Swick & Foti law firm are investigating the proposed sale of RAPT Therapeutics to GSK, aiming to assess the adequacy of the transaction process and its terms.
- Transaction Terms Overview: Under the proposed terms, RAPT shareholders will receive $58.00 in cash per share, raising questions about whether this price adequately reflects the company's value, necessitating further scrutiny.
- Legal Rights Consultation: KSF encourages shareholders who believe the transaction undervalues the company to reach out for discussions regarding their legal rights, indicating potential disputes surrounding the deal.
- Urgency Reminder: As the transaction is structured as a tender offer, KSF emphasizes the importance of prompt action by shareholders to ensure their rights are protected.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Initiated: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc. (NASDAQ: RAPT) regarding its sale to GSK plc for $58.00 per share, potentially violating fiduciary duties to shareholders and impacting shareholder rights.
- Shareholder Rights Protection: The transaction between Penumbra, Inc. (NYSE: PEN) and Boston Scientific Corporation involves $374.00 in cash or 3.8721 shares of Boston Scientific common stock per share, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
- Cash and Stock Transaction: Calavo Growers, Inc. (NASDAQ: CVGW) is selling to Mission Produce, Inc. for $14.85 in cash and 0.9790 shares of Mission stock per share, prompting Halper Sadeh LLC to assess the potential impact of this transaction on shareholders.
- Management Transaction Review: FONAR Corporation (NASDAQ: FONR) is involved in a transaction with its CEO and certain executives for $19.00 per share for Class B common stock and $6.34 per share for Class C common stock, with Halper Sadeh LLC possibly advocating for enhanced shareholder rights.
See More
Investigation Alerts for Multiple Company Mergers
- RAPT Acquisition Investigation: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, totaling an estimated equity value of $2.2 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
- Calavo Merger Details: Calavo Growers will be acquired by Mission Produce, with shareholders receiving $27 per share, including $14.85 in cash and 0.9790 shares of Mission, valuing the transaction at approximately $430 million, while investigations examine if the board breached fiduciary duties to shareholders.
- Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific in a deal valuing the company at $374 per share, reflecting an enterprise value of about $14.5 billion, with investigations looking into whether the board ensured a fair process, potentially affecting shareholder interests.
- FONAR Merger Investigation: FONAR Corporation is to be acquired by FONAR, LLC for $19 per share in an all-cash transaction, with investigations questioning whether the board failed to conduct a fair process, which could impact shareholder rights.
See More
